{"id":5305,"date":"2021-04-30T10:22:05","date_gmt":"2021-04-30T08:22:05","guid":{"rendered":"https:\/\/staybletherapeutics.com\/sv\/?p=5305"},"modified":"2021-04-30T10:22:05","modified_gmt":"2021-04-30T08:22:05","slug":"inside-stayble-april-2021","status":"publish","type":"post","link":"https:\/\/staybletherapeutics.com\/sv\/presentationer\/inside-stayble-april-2021\/","title":{"rendered":"Inside Stayble: April 2021"},"content":{"rendered":"<p><span style=\"color: #333333;\">I april 2021 uppdateringen reflekterar VD Andreas Gerward \u00f6ver den p\u00e5g\u00e5ende kliniska fas 2b studien, rekryteringen av Sara Richardson till den nya rollen VP CMC &amp; Regulatory Affairs samt ger en \u00f6versikt kring p\u00e5g\u00e5ende partneringdiskussioner<br \/>\nInside Stayble \u00e4r en kommunikationskanal f\u00f6r att ge aktie\u00e4gare m\u00e5nadsvisa uppdateringar om Stayble Therapeutics och det kliniska utvecklingsprogrammet f\u00f6r STA363 i kronisk l\u00e4ndryggssm\u00e4rta.<\/span><\/p>\n<p>Stayble Therapeutics \u00e4r listat p\u00e5 Nasdaq First North (STABL).<\/p>\n<p>L\u00e4s mer p\u00e5 <a href=\"http:\/\/staybletherapeutics.se\">staybletherapeutics.se<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>I april 2021 uppdateringen reflekterar VD Andreas Gerward \u00f6ver den p\u00e5g\u00e5ende kliniska fas 2b studien, rekryteringen av Sara Richardson till den nya rollen VP CMC &amp; Regulatory Affairs samt ger&#8230;<\/p>\n","protected":false},"author":1,"featured_media":5178,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/posts\/5305"}],"collection":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=5305"}],"version-history":[{"count":2,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/posts\/5305\/revisions"}],"predecessor-version":[{"id":5308,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/posts\/5305\/revisions\/5308"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media\/5178"}],"wp:attachment":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=5305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/categories?post=5305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/tags?post=5305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}